Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Roche has done more research on P53 than any other big Pharma company. IMO Roche is the favorite to partner with CTIX for developing Kevetrin

http://www.roche.com/med_mb200605lv.pdf

Roche's Nutlin drugs have severe side effects including bone marrow suppression which have limited their progress in the FDA clinical trials.

Many pediatric tumors are linked to p53 abnormalities and respond to p53 activation. If Kevetrin proves to be successful in its Retinoblastoma trial, Kevetrin will be studied in a number of childhood cancers including Neuroblastoma, ALL, Rhabdomyosarcoma, Ewing's sarcoma and Osteosarcoma.The articles below summarizes p53 activation including Roche's Nutlins. Kevetrin is mentioned in the first article.

http://www.ingentaconnect.com/content/ben/cdt/2014/00000015/00000001/art00010?crawler=true

http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM426179.pdf

It is interesting and pertinent to Kevetrin to review the preclinical and clinical work done by Roche on the Nutlins. Since the Nutlins and Kevetrin both activate P53, the safer drug will progress through the FDA trials. If Kevetrin continues to perform well in the clinical trials, we can expect FDA phase 2 and 3 studies for Kevetrin in virtually all the cancers the Nutlins were shown to have activity against.

GLTA Farrell